financetom
Business
financetom
/
Business
/
Nanobiotix Doses First Patient in Phase 2 Study of Lung Cancer Therapy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nanobiotix Doses First Patient in Phase 2 Study of Lung Cancer Therapy
Jan 21, 2025 12:57 AM

03:39 AM EST, 01/21/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Tuesday it dosed the first patient in a phase 2 trial testing the experimental drug, JNJ-1900, for stage 3 non-small cell lung cancer.

The study is sponsored by Johnson & Johnson's ( JNJ ) subsidiary, Janssen Pharmaceutical, under a global licensing agreement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Privia Health Q3 revenue up 32.5%, raises FY forecast
Privia Health Q3 revenue up 32.5%, raises FY forecast
Nov 6, 2025
Overview * Privia Health ( PRVA ) Q3 revenue grows 32.5% yr/yr but misses analyst expectations * Adjusted EBITDA for Q3 beats consensus * Company raises FY'25 guidance above high end for key metrics Outlook * Privia Health ( PRVA ) raises FY'25 revenue guidance to $2.05 bln-$2.1 bln * Company expects FY'25 adjusted EBITDA of $118 mln-$121 mln *...
Dorian LPG Q2 revenue beats estimates, declares dividend 
Dorian LPG Q2 revenue beats estimates, declares dividend 
Nov 6, 2025
Overview * Dorian LPG ( LPG ) fiscal Q2 revenue grows 50.5%, beating analyst expectations * Net income for fiscal Q2 rises to $55.4 mln, adjusted EBITDA at $85.7 mln * Company declares irregular cash dividend of $0.65 per share, totaling $27.8 mln Outlook * Company notes geopolitical factors continue to influence LPG market conditions * Dorian LPG ( LPG...
Sylogist Q3 revenue down 4.2%
Sylogist Q3 revenue down 4.2%
Nov 6, 2025
Overview * Sylogist ( SYZLF ) fiscal Q3 total revenue declines 4.2% yr/yr * SaaS subscription revenue grows 11.9% yr/yr, reflecting transformation to SaaS-driven enterprise * Adjusted EBITDA margin at 19.3%, net income negative Outlook * Company did not provide specific financial guidance for future quarters Result Drivers * PARTNER STRATEGY - 48% of ARR Bookings in Q3 were partner-driven,...
KFC's India operator Devyani posts quarterly loss as demand stays muted
KFC's India operator Devyani posts quarterly loss as demand stays muted
Nov 6, 2025
Nov 6 (Reuters) - Devyani International, which operates KFC ( YUM ) and Pizza Hut restaurants in India, reported a quarterly loss on Thursday, as demand across its portfolio remained under pressure. The company, which is one of Yum Brands ( YUM ) two franchisees in India, said that Yum's strategic review of its struggling Pizza Hut chain will not...
Copyright 2023-2026 - www.financetom.com All Rights Reserved